TP53 and neoplasm: Thus, we confirmed in a third independent cohort that BCs with bi-allelic loss of CHEK2 do not harbor somatic TP53 mutations and that the unfavorable survival of CHEK2 c.1100delC carriers is likely driven by intrinsic tumor aggressiveness rather than endocrine resistance.